Fallopian tube cancer+2
Not recruitingStudy on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment
Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment
- Disease:Fallopian tube cancerOvarian cancer+1
- Substances:BevacizumabDostarlimab+5
Germany- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS











